Ketamine for unipolar depression: A systematic review of efficacy and safety.
Study Goal
The researchers aimed to evaluate the efficacy and safety of ketamine as a rapid-acting antidepressant for treatment-resistant unipolar depression.
Results Summary
Ketamine significantly reduced depressive symptoms and suicidal ideation within hours, with effects lasting up to 1 week, but common side effects included transient dissociation, elevated blood pressure, nausea, and dizziness. Long-term safety remains uncertain.
Population
Individuals with formally diagnosed unipolar depression, particularly treatment-resistant cases.
Effective Dosage
Not specified in the abstract.
Duration
Effects observed within hours, lasting up to 1 week (intervention duration not specified).
Interactions
None mentioned.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
ketamine | decrease | depressive symptoms | formally diagnosed individuals | - | significantly reduced | #1 |
ketamine | decrease | suicidal ideation | formally diagnosed individuals | - | significantly reduced | #2 |
ketamine | decrease | depressive symptoms | formally diagnosed individuals | 1 week | effects lasting up to | #3 |
ketamine | increase | transient dissociation | formally diagnosed individuals | - | common side effects included | #4 |
ketamine | increase | elevated blood pressure | formally diagnosed individuals | - | common side effects included | #5 |
ketamine | increase | nausea | formally diagnosed individuals | - | common side effects included | #6 |
ketamine | increase | dizziness | formally diagnosed individuals | - | common side effects included | #7 |
BackgroundUnipolar depression is a prevalent mental health disorder with persistent, treatment-resistant symptoms. Traditional antidepressants take weeks to show effects, underscoring the need for faster alternatives. Ketamine, originally an anaesthetic, has emerged as a rapid-acting antidepressant.ObjectiveThis systematic review evaluates ketamine's efficacy and safety in unipolar depression.MethodsA literature search (January 2000-May 2024) in PubMed, PsycINFO, and Cochrane Library included RCTs, CCTs, systematic reviews, meta-analyses, and observational studies on ketamine or esketamine in formally diagnosed individuals. Study characteristics, interventions, outcomes, and adverse events were analyzed, with quality and bias assessments.ResultsAcross 44 studies, ketamine significantly reduced depressive symptoms and suicidal ideation within hours, particularly in treatment-resistant cases, with effects lasting up to 1 week. Common side effects included transient dissociation, elevated blood pressure, nausea, and dizziness, while long-term safety remains uncertain.ConclusionsKetamine shows promise as a rapid antidepressant for treatment-resistant unipolar depression. However, long-term safety and optimal treatment protocols require further research. Careful clinical integration with monitoring is recommended.